Non-Hodgkin's lymphoma in adolescents: Experiences in 378 adolescent NHL patients treated according to pediatric NHL-BFM protocols

Leukemia

Volumn 25, Issue 1, 2011, Pages 153-160

  Burkhardt, B ^a   Oschlies, I ^b   Klapper, W ^b   Zimmermann, M ^a   Woessmann, W ^a   Meinhardt, A ^a   Landmann, E ^a   Attarbaschi, A ^c   Niggli, F ^d   Schrappe, M ^b   Reiter, A ^a  

^a JUSTUS LIEBIG UNIVERSITY   (Germany)

^b UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^c ST ANNA CHILDREN S HOSPITAL   (Austria)

^d UNIVERSITY CHILDREN S HOSPITAL   (Switzerland)

Author keywords

adolescents; non Hodgkin's lymphoma; pediatric protocols

Indexed keywords

ASPARAGINASE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYTARABINE; DAUNORUBICIN; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; IFOSFAMIDE; LACTATE DEHYDROGENASE; MERCAPTOPURINE; METHOTREXATE; TIOGUANINE; VINCRISTINE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ARTICLE; B CELL LYMPHOMA; BLOOD SMEAR; BONE MARROW BIOPSY; BURKITT LYMPHOMA; CANCER COMBINATION CHEMOTHERAPY; CANCER REGISTRY; CHILDHOOD CANCER; CLINICAL PROTOCOL; CLINICAL TRIAL (TOPIC); DRUG DOSE REGIMEN; DRUG INTERMITTENT THERAPY; DRUG MEGADOSE; DRUG PULSE THERAPY; EVENT FREE SURVIVAL; FEMALE; FOLLOW UP; GROUPS BY AGE; HUMAN; LARGE CELL LYMPHOMA; LYMPHOBLASTOMA; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; NONHODGKIN LYMPHOMA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; RETROSPECTIVE STUDY; SEX DIFFERENCE; SINGLE DRUG DOSE;

EID: 78651295815     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2010.245     Document Type: Article

References (59)

1. Percy CL, Smith MA, Linet M, Lynn A, Ries LAG, Friedman D et al. Lymphomas and Reticuloendothelial Neoplasms. Cancer Incidence and Survival among Children and Adolescents: United States SEER Program 1975-1995, vol NIH Pub. No. 99-4649. National Cancer Institute, SEER Program: Bethesda, 1999, pp 35-49.
2. Hochberg J, Waxman IM, Kelly KM, Morris E, Cairo MS. Adolescent non-Hodgkin lymphoma and Hodgkin lymphoma: state of the science. Br J Haematol 2009; 144: 24-40.
3. Jaglowski SM, Linden E, Termuhlen AM, Flynn JM. Lymphoma in adolescents and young adults. Semin Oncol 2009; 36: 381-418.
4. Sandlund JT. Should adolescents with NHL be treated as old children or young adults? Hematology Am Soc Hematol Educ Program 2007; 2007: 297-303.
5. Boissel N, Auclerc MF, Lheritier V, Perel Y, Thomas X, Leblanc T et al. Should adolescents with acute lymphoblastic leukemia be treated as old children or young adults? Comparison of the French FRALLE-93 and LALA-94 trials. J Clin Oncol 2003; 21: 774-780.
6. de Bont JM, Holt B, Dekker AW, van der Does-van den Berg A, Sonneveld P, Pieters R. Significant difference in outcome for adolescents with acute lymphoblastic leukemia treated on pediatric vs adult protocols in the Netherlands. Leukemia 2004; 18: 2032-2035.
7. Hallbook H, Gustafsson G, Smedmyr B, Soderhall S, Heyman M. Treatment outcome in young adults and children 410 years of age with acute lymphoblastic leukemia in Sweden: a comparison between a pediatric protocol and an adult protocol. Cancer 2006; 107: 1551-1561.
8. Ramanujachar R, Richards S, Hann I, Goldstone A, Mitchell C, Vora A et al. Adolescents with acute lymphoblastic leukaemia: outcome on UK national paediatric (ALL97) and adult (UKALLXII/ E2993) trials. Pediatr Blood Cancer 2007; 48: 254-261.
9. Schroder H, Kjeldahl M, Boesen AM, Nielsen OJ, Schmidt K, Johnsen HE et al. Acute lymphoblastic leukemia in adolescents between 10 and 19 years of age in DenmarkFsecondary publication. Dan Med Bull 2006; 53: 76-79.
10. Stock W, La M, Sanford B, Bloomfield CD, Vardiman JW, Gaynon P et al. What determines the outcomes for adolescents and young adults with acute lymphoblastic leukemia treated on cooperative group protocols? A comparison of Children's Cancer Group and Cancer and Leukemia Group B studies. Blood 2008; 112: 1646-1654.
11. Burkhardt B, Zimmermann M, Oschlies I, Niggli F, Mann G, Parwaresch R et al. The impact of age and gender on biology, clinical features and treatment outcome of non-Hodgkin lymphoma in childhood and adolescence. Br J Haematol 2005; 131: 39-49.
12. Murphy SB. Classification, staging and end results of treatment of childhood non-Hodgkin's lymphomas: dissimilarities from lympho-mas in adults. Semin Oncol 1980; 7: 332-339.
13. Oschlies I, Klapper W, Zimmermann M, Krams M, Wacker HH, Burkhardt B et al. Diffuse large B-cell lymphoma in pediatric patients belongs predominantly to the germinal-center type B-cell lymphomas: a clinicopathologic analysis of cases included in the German BFM (Berlin-Frankfurt-Munster) Multicenter Trial. Blood 2006; 107: 4047-4052.
14. Reiter A, Klapper W. Recent advances in the understanding and management of diffuse large B-cell lymphoma in children. Br J Haematol 2008; 142: 329-347.
15. Reiter A, Schrappe M, Parwaresch R, Henze G, Muller-Weihrich S, Sauter S et al. Non-Hodgkin's lymphomas of childhood and adolescence: results of a treatment stratified for biologic subtypes and stageFa report of the Berlin-Frankfurt-Munster Group. J Clin Oncol 1995; 13: 359-372.
16. Reiter A, Schrappe M, Ludwig WD, Tiemann M, Parwaresch R, Zimmermann M et al. Intensive ALL-type therapy without local radiotherapy provides a 90% event-free survival for children with T-cell lymphoblastic lymphoma: a BFM group report. Blood 2000; 95: 416-421.
17. Burkhardt B, Woessmann W, Zimmermann M, Kontny U, Vormoor J, Doerffel W et al. Impact of cranial radiotherapy on central nervous system prophylaxis in children and adolescents with central nervous system-negative stage III or IV lymphoblastic lymphoma. J Clin Oncol 2006; 24: 491-499.
18. Seidemann K, Tiemann M, Schrappe M, Yakisan E, Simonitsch I, Janka-Schaub G et al. Short-pulse B-non-Hodgkin lymphoma-type chemotherapy is efficacious treatment for pediatric anaplastic large cell lymphoma: a report of the Berlin-Frankfurt-Munster Group Trial NHL-BFM 90. Blood 2001; 97: 3699-3706.
19. Woessmann W, Seidemann K, Mann G, Zimmermann M, Burkhardt B, Oschlies I et al. The impact of the methotrexate administration schedule and dose in the treatment of children and adolescents with B-cell neoplasms: a report of the BFM Group Study NHL-BFM95. Blood 2005; 105: 948-958.
20. Brugieres L, Le Deley MC, Rosolen A, Williams D, Horibe K, Wrobel G et al. Impact of the methotrexate administration dose on the need for intrathecal treatment in children and adolescents with anaplastic large-cell lymphoma: results of a randomized trial of the EICNHL Group. J Clin Oncol 2009; 27: 897-903.
21. Reiter A, Schrappe M, Tiemann M, Ludwig WD, Yakisan E, Zimmermann M et al. Improved treatment results in childhood B-cell neoplasms with tailored intensification of therapy: a report of the Berlin-Frankfurt-Munster Group Trial NHL-BFM 90. Blood 1999; 94: 3294-3306.
22. Kaplan EL, Meier P. Non-parametric estimation from incomplete observations. J Am Stat Assos 1958; 53: 457-481.
23. Mantel E. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 1966; 50: 163-170.
24. Kaatsch P, Spix C. German Childhood Cancer Registry, Annual Report 2006/07. German Childhood Cancer Registry: Mainz, Germany, 2007.
25. Eden OB, Hann I, Imeson J, Cotterill S, Gerrard M, Pinkerton CR. Treatment of advanced stage T cell lymphoblastic lymphoma: results of the United Kingdom Children's Cancer Study Group (UKCCSG) protocol 8503. Br J Haematol 1992; 82: 310-316.
26. Amylon MD, Shuster J, Pullen J, Berard C, Link MP, Wharam M et al. Intensive high-dose asparaginase consolidation improves survival for pediatric patients with T cell acute lymphoblastic leukemia and advanced stage lymphoblastic lymphoma: a Pediatric Oncology Group study. Leukemia 1999; 13: 335-342.
27. Abromowitch M, Sposto R, Perkins S, Zwick D, Siegel S, Finlay J et al. Shortened intensified multi-agent chemotherapy and non-cross resistant maintenance therapy for advanced lymphoblastic lymphoma in children and adolescents: report from the Children's Oncology Group. Br J Haematol 2008; 143: 261-267.
28. Tubergen DG, Krailo MD, Meadows AT, Rosenstock J, Kadin M, Morse M et al. Comparison of treatment regimens for pediatric lymphoblastic non-Hodgkin's lymphoma: a Childrens Cancer Group study. J Clin Oncol 1995; 13: 1368-1376.
29. Hoelzer D, Gokbuget N, Digel W, Faak T, Kneba M, Reutzel R et al. Outcome of adult patients with T-lymphoblastic lymphoma treated according to protocols for acute lymphoblastic leukemia. Blood 2002; 99: 4379-4385.
30. Baleydier F, Decouvelaere AV, Bergeron J, Gaulard P, Canioni D, Bertrand Y et al. T cell receptor genotyping and HOXA/TLX1 expression define three T lymphoblastic lymphoma subsets which might affect clinical outcome. Clin Cancer Res 2008; 14: 692-700.
31. Patte C, Auperin A, Michon J, Behrendt H, Leverger G, Frappaz D et al. The Societe Francaise d'Oncologie Pediatrique LMB89 protocol: highly effective multiagent chemotherapy tailored to the tumor burden and initial response in 561 unselected children with B-cell lymphomas and L3 leukemia. Blood 2001; 97: 3370-3379.
32. Cairo MS, Sposto R, Perkins SL, Meadows AT, Hoover-Regan ML, Anderson JR et al. Burkitt's and Burkitt-like lymphoma in children and adolescents: a review of the Children's Cancer Group experience. Br J Haematol 2003; 120: 660-670.
33. Pillon M, Di Tullio MT, Garaventa A, Cesaro S, Putti MC, Favre C et al. Long-term results of the first Italian Association of Pediatric Hematology and Oncology protocol for the treatment of pediatric B-cell non-Hodgkin lymphoma (AIEOP LNH92). Cancer 2004; 101: 385-394.
34. Trautmann H, Hadzidimitriou A, Darzentas N, Klapper W, Siebert R, Berger H et al. Evidence for antigen-driven development of molecularly classified Burkitt lymphomas. Blood 2009; 114, Abstract 317.
35. Alizadeh AA, Eisen MB, Davis RE, Ma C, Lossos IS, Rosenwald A et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 2000; 403: 503-511.
36. Rosenwald A, Wright G, Chan WC, Connors JM, Campo E, Fisher RI et al. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med 2002; 346: 1937-1947.
37. Hans CP, Weisenburger DD, Greiner TC, Gascoyne RD, Delabie J, Ott G et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood 2004; 103: 275-282.
38. Miles RR, Raphael M, McCarthy K, Wotherspoon A, Lones MA, Terrier-Lacombe MJ et al. Pediatric diffuse large B-cell lymphoma demonstrates a high proliferation index, frequent c-Myc protein expression, and a high incidence of germinal center subtype: report of the French-American-British (FAB) international study group. Pediatr Blood Cancer 2008; 51: 369-374.
39. Klapper W, Szczepanowski M, Burkhardt B, Berger H, Rosolowski M, Bentink S et al. Molecular profiling of pediatric mature B-cell lymphoma treated in population-based prospective clinical trials. Blood 2008; 112: 1374-1381.
40. A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project. N Engl J Med 1993; 329: 987-994.
41. Sehn LS, Donaldson J, Chhanabhi M, Fitzgerald M, Gill K, Klasa R et al. Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma in British Columbia. J Clin Oncol 2005; 23: 5027-5033.
42. Coiffier B, Thieblemont C, Van Den Neste E, Lepeu G, Plantier I, Castaigne S et al. Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte. Blood 2010, e-pub ahead of print 14 June 2010.
43. Gaulard P, Harris NL, Pileri SA, Kutok JL, Stein H, Kovrigina AM et al. Primary mediastinal (thymic) large B-cell lymphoma. In: Swerdlow S, Campo E, Harris N, Jaffe E, Pileri S, Stein H, et al. (eds). WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, 4th edn International Agency for Research on Cancer: Lyon, 2008, pp 250-251.
44. Seidemann K, Tiemann M, Lauterbach I, Mann G, Simonitsch I, Stankewitz K et al. Primary mediastinal large B-cell lymphoma with sclerosis in pediatric and adolescent patients: treatment and results from three therapeutic studies of the Berlin-Frankfurt-Munster Group. J Clin Oncol 2003; 21: 1782-1789.
45. Lazzarino M, Orlandi E, Paulli M, Strater J, Klersy C, Gianelli U et al. Treatment outcome and prognostic factors for primary mediastinal (thymic) B-cell lymphoma: a multicenter study of 106 patients. J Clin Oncol 1997; 15: 1646-1653.
46. Zinzani PL, Martelli M, Magagnoli M, Pescarmona E, Scaramucci L, Palombi F et al. Treatment and clinical management of primary mediastinal large B-cell lymphoma with sclerosis: MACOP-B regimen and mediastinal radiotherapy monitored by (67)Gallium scan in 50 patients. Blood 1999; 94: 3289-3293.
47. Todeschini G, Secchi S, Morra E, Vitolo U, Orlandi E, Pasini F et al. Primary mediastinal large B-cell lymphoma (PMLBCL): long-term results from a retrospective multicentre Italian experience in 138 patients treated with CHOP or MACOP-B/VACOP-B. Br J Cancer 2004; 90: 372-376.
48. Savage KJ, Al-Rajhi N, Voss N, Paltiel C, Klasa R, Gascoyne RD et al. Favorable outcome of primary mediastinal large B-cell lymphoma in a single institution: the British Columbia experience. Ann Oncol 2006; 17: 123-130.
49. Dunleavy K, Pittaluga S, Tay K, Grant N, Chen C, Shovlin M et al. Comparative clinical and biological features of primary mediastinal B-cell lymphoma (PMBL) and mediastinal grey zone lymphoma (MGZL). Blood 2009; 114: Abstract 106.
50. Brugieres L, Deley MC, Pacquement H, Meguerian-Bedoyan Z, Terrier-Lacombe MJ, Robert A et al. CD30(+) anaplastic large-cell lymphoma in children: analysis of 82 patients enrolled in two consecutive studies of the French Society of Pediatric Oncology. Blood 1998; 92: 3591-3598.
51. Williams DM, Hobson R, Imeson J, Gerrard M, McCarthy K, Pinkerton CR. Anaplastic large cell lymphoma in childhood: analysis of 72 patients treated on The United Kingdom Children's Cancer Study Group chemotherapy regimens. Br J Haematol 2002; 117: 812-820.
52. Le Deley MC, Reiter A, Williams D, Delsol G, Oschlies I, McCarthy K et al. Prognostic factors in childhood anaplastic large cell lymphoma: results of a large European intergroup study. Blood 2008; 111: 1560-1566.
53. Falini B, Pileri S, Zinzani PL, Carbone A, Zagonel V, Wolf-Peeters C et al. ALK+ lymphoma: clinico-pathological findings and outcome. Blood 1999; 93: 2697-2706.
54. Stein H, Foss HD, Durkop H, Marafioti T, Delsol G, Pulford K et al. CD30(+) anaplastic large cell lymphoma: a review of its histopathologic, genetic, and clinical features. Blood 2000; 96: 3681-3695.
55. Coleman CN, Picozzi Jr VJ, Cox RS, McWhirter K, Weiss LM, Cohen JR et al. Treatment of lymphoblastic lymphoma in adults. J Clin Oncol 1986; 4: 1628-1637.
56. Thomas DA, O'Brien S, Cortes J, Giles FJ, Faderl S, Verstovsek S et al. Outcome with the hyper-CVAD regimens in lymphoblastic lymphoma. Blood 2004; 104: 1624-1630.
57. Morel P, Lepage E, Brice P, Dupriez B, D'Agay MF, Fenaux P et al. Prognosis and treatment of lymphoblastic lymphoma in adults: a report on 80 patients. J Clin Oncol 1992; 10: 1078-1085.
58. Gascoyne RD, Aoun P, Wu D, Chhanabhai M, Skinnider BF, Greiner TC et al. Prognostic significance of anaplastic lymphoma kinase (ALK) protein expression in adults with anaplastic large cell lymphoma. Blood 1999; 93: 3913-3921.
59. Savage KJ, Harris NL, Vose JM, Ullrich F, Jaffe ES, Connors JM et al. ALK- anaplastic large-cell lymphoma is clinically and immuno-phenotypically different from both ALK+ ALCL and peripheral T-cell lymphoma, not otherwise specified: report from the International Peripheral T-Cell Lymphoma Project. Blood 2008; 111: 5496-5504.